19.07

0.00% 0.00

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $19.07, with a volume of 1.55M. It is up +0.00% in the last 24 hours and up +56.70% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Previous Close:

$19.07

Open:

$19.07

24h Volume:

1.55M

Relative Volume:

0.95

Market Cap:

$1.93B

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-6.5986

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

+5.42%

1M Performance:

+56.70%

6M Performance:

+59.45%

1Y Performance:

-7.25%

1-Day Range:

$19.06

$19.68

1-Week Range:

$19.02

$22.50

52-Week Range:

$8.18

$22.50

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

286

Twitter

Next Earnings Date

2025-10-09

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	19.07	1.93B	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

06:14 AM